Status:
UNKNOWN
Cystic Fibrosis (CF) Exacerbation and Insulin Treatment
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Cystic Fibrosis
Impaired Glucose Tolerance
Eligibility:
All Genders
10+ years
Phase:
NA
Brief Summary
The purpose of the study is to evaluate whether insulin treatment during pulmonary exacerbation (PE) in patients with Cystic Fibrosis (CF)and normoglycemia improves their short term outcome by normali...
Detailed Description
The life expectancy of patients with cystic fibrosis (CF) has increased over the last decades due to improved understanding of the disease and new treatments. CF patients who live longer develop gluco...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of CF according to standard criteria
- Pancreatic insufficiency
- Age \> 10 years
- Normal oral glucose tolerance test (OGTT) in the past 12 month.
- Acute pulmonary exacerbation (PE) according to the treating physician requires treatment with intravenous antibiotics
Exclusion
- CF-related diabetes/impaired glucose tolerance test (IGTT) in a mixed meal tolerance test performed during full remission from pulmonary exacerbation
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01149005
Start Date
June 1 2010
End Date
December 1 2015
Last Update
June 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Hospital
Jerusalem, Israel